Symbols / SLDB
SLDB Chart
About
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 481.49M |
| Enterprise Value | 267.28M | Income | -167.14M | Sales | — |
| Book/sh | 2.80 | Cash/sh | 3.03 | Dividend Yield | — |
| Payout | 0.00% | Employees | 100 | IPO | — |
| P/E | — | Forward P/E | -3.03 | PEG | — |
| P/S | — | P/B | 2.21 | P/C | — |
| EV/EBITDA | -1.59 | EV/Sales | — | Quick Ratio | 6.50 |
| Current Ratio | 6.74 | Debt/Eq | 10.06 | LT Debt/Eq | — |
| EPS (ttm) | -2.48 | EPS next Y | -2.04 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 | ROA | -43.67% |
| ROE | -86.83% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 77.91M |
| Shs Float | 37.90M | Short Float | 13.21% | Short Ratio | 8.38 |
| Short Interest | — | 52W High | 7.37 | 52W Low | 2.41 |
| Beta | 2.65 | Avg Volume | 1.06M | Volume | 919.78K |
| Target Price | $15.75 | Recom | Strong_buy | Prev Close | $5.87 |
| Price | $6.18 | Change | 5.28% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.75
Mean price target
2. Current target
$6.18
Latest analyst target
3. DCF / Fair value
$-17.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.18
Low
$11.00
High
$20.00
Mean
$15.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-09 | reit | Needham | Buy → Buy | $16 |
| 2026-01-14 | reit | Needham | Buy → Buy | $16 |
| 2025-12-04 | init | Needham | — → Buy | $16 |
| 2025-11-05 | main | Citigroup | Buy → Buy | $14 |
| 2025-11-05 | main | JP Morgan | Overweight → Overweight | $11 |
| 2025-11-04 | main | Barclays | Overweight → Overweight | $9 |
| 2025-11-04 | main | Chardan Capital | Buy → Buy | $15 |
| 2025-08-14 | main | Chardan Capital | Buy → Buy | $15 |
| 2025-08-14 | main | JP Morgan | Overweight → Overweight | $13 |
| 2025-08-13 | main | Wedbush | Outperform → Outperform | $14 |
| 2025-06-26 | init | Citigroup | — → Buy | $14 |
| 2025-06-17 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-06-06 | reit | JMP Securities | Market Outperform → Market Outperform | $15 |
| 2025-05-19 | main | Chardan Capital | Buy → Buy | $15 |
| 2025-05-16 | main | Piper Sandler | Overweight → Overweight | $17 |
| 2025-05-16 | main | Wedbush | Outperform → Outperform | $17 |
| 2025-05-16 | main | Barclays | Overweight → Overweight | $10 |
| 2025-03-13 | main | JP Morgan | Overweight → Overweight | $11 |
| 2025-03-10 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-03-07 | main | Chardan Capital | Buy → Buy | $16 |
- Solid Biosciences chief regulatory officer Hanrahan sells $24k in SLDB stock - Investing.com Nigeria hu, 19 Feb 2026 04
- Insider Sale: Chief Medical Officer of $SLDB Sells 28,335 Shares - Quiver Quantitative ue, 03 Feb 2026 08
- Technical Reactions to SLDB Trends in Macro Strategies - Stock Traders Daily Sat, 21 Feb 2026 16
- FDA backs Phase 3 plan for Duchenne gene therapy SGT-003 - Stock Titan Mon, 09 Feb 2026 08
- Solid Biosciences: Positive FDA Meeting SGT-003 Sets Up Next Milestones (NASDAQ:SLDB) - Seeking Alpha Mon, 09 Feb 2026 08
- Solid Biosciences CTO Herzich sells $70k in SLDB stock - Investing.com Fri, 06 Feb 2026 08
- Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT - Yahoo Finance Wed, 09 Jul 2025 07
- $SLDB stock is down 10% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Feb 2026 19
- Director Ilan Ganot linked sale of 7,205 Solid Biosciences (SLDB) shares disclosed - Stock Titan Fri, 06 Feb 2026 08
- Insider Sale: President and CEO of $SLDB Sells 16,644 Shares - Quiver Quantitative hu, 19 Feb 2026 02
- Solid Bio aligns with FDA on late-stage trial design for Duchenne drug - Seeking Alpha Mon, 09 Feb 2026 08
- Sarepta’s Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences’ (SLDB) SGT-003 in Duchenne Therapy - Yahoo Finance Mon, 15 Dec 2025 08
- U.S. newborns will now be screened for Duchenne muscular dystrophy - Stock Titan ue, 16 Dec 2025 08
- $SLDB stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Wed, 14 Jan 2026 08
- $SLDB stock is down 16% today. Here's what we see in our data. - Quiver Quantitative ue, 04 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 7469 | 43494.0 | — | Sale at price 5.82 per share. | HOWTON DAVID TYRONNE | Chief Operating Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 16644 | 96923.0 | — | Sale at price 5.82 per share. | CUMBO ALEXANDER | Chief Executive Officer | — | 2026-02-18 00:00:00 | D |
| 2 | 2658 | 15478.0 | — | Sale at price 5.82 per share. | GANOT ILAN | Director | — | 2026-02-18 00:00:00 | I |
| 3 | 5404 | 31469.0 | — | Sale at price 5.82 per share. | TAN KEVIN | Chief Financial Officer | — | 2026-02-18 00:00:00 | D |
| 4 | 4134 | 24074.0 | — | Sale at price 5.82 per share. | HANRAHAN JESSIE | Officer | — | 2026-02-18 00:00:00 | D |
| 5 | 3616 | 21057.0 | — | Sale at price 5.82 per share. | HERZICH PAUL | Chief Technology Officer | — | 2026-02-18 00:00:00 | D |
| 6 | 89466 | 529639.0 | — | Sale at price 5.92 per share. | BROOKS GABRIEL M.D. | Officer | — | 2026-02-18 00:00:00 | D |
| 7 | 14687 | nan | — | — | HOWTON DAVID TYRONNE | Chief Operating Officer | — | 2026-02-13 00:00:00 | D |
| 8 | 30031 | nan | — | — | CUMBO ALEXANDER | Chief Executive Officer | — | 2026-02-13 00:00:00 | D |
| 9 | 4861 | nan | — | — | GANOT ILAN | Director | — | 2026-02-13 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -117.15M | -93.06M | -107.92M | -69.29M |
| TotalUnusualItems | -4.75M | 63.00K | 11.06M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -4.75M | 63.00K | 11.06M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -124.70M | -96.02M | -85.98M | -72.19M |
| ReconciledDepreciation | 2.46M | 2.58M | 2.41M | 2.96M |
| EBITDA | -121.90M | -92.99M | -96.87M | -69.29M |
| EBIT | -124.36M | -95.58M | -99.27M | -72.25M |
| NetInterestIncome | 9.13M | 7.14M | 2.62M | 64.00K |
| InterestExpense | 340.00K | 440.00K | ||
| InterestIncome | 9.47M | 7.58M | 2.62M | 64.00K |
| NormalizedIncome | -119.95M | -96.08M | -97.04M | -72.19M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -124.70M | -96.02M | -85.98M | -72.19M |
| TotalExpenses | 129.73M | 104.31M | 107.37M | 85.87M |
| TotalOperatingIncomeAsReported | -129.73M | -104.25M | -106.45M | -72.25M |
| DilutedAverageShares | 40.82M | 19.88M | 8.51M | 7.12M |
| BasicAverageShares | 40.82M | 19.88M | 8.51M | 7.12M |
| DilutedEPS | -3.06 | -4.83 | -10.10 | -10.14 |
| BasicEPS | -3.06 | -4.83 | -10.10 | -10.14 |
| DilutedNIAvailtoComStockholders | -124.70M | -96.02M | -85.98M | -72.19M |
| NetIncomeCommonStockholders | -124.70M | -96.02M | -85.98M | -72.19M |
| NetIncome | -124.70M | -96.02M | -85.98M | -72.19M |
| NetIncomeIncludingNoncontrollingInterests | -124.70M | -96.02M | -85.98M | -72.19M |
| NetIncomeContinuousOperations | -124.70M | -96.02M | -85.98M | -72.19M |
| PretaxIncome | -124.70M | -96.02M | -85.98M | -72.19M |
| OtherIncomeExpense | -4.10M | 1.16M | 10.68M | 2.00K |
| OtherNonOperatingIncomeExpenses | 652.00K | 1.09M | -381.00K | 2.00K |
| SpecialIncomeCharges | 0.00 | 63.00K | 11.06M | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | -63.00K | -11.06M | 0.00 |
| GainOnSaleOfSecurity | -4.75M | |||
| NetNonOperatingInterestIncomeExpense | 9.13M | 7.14M | 2.62M | 64.00K |
| TotalOtherFinanceCost | -2.62M | -64.00K | ||
| InterestExpenseNonOperating | 340.00K | 440.00K | ||
| InterestIncomeNonOperating | 9.47M | 7.58M | 2.62M | 64.00K |
| OperatingIncome | -129.73M | -104.31M | -99.27M | -72.25M |
| OperatingExpense | 129.73M | 104.31M | 107.37M | 85.87M |
| ResearchAndDevelopment | 96.43M | 76.56M | 78.42M | 58.74M |
| SellingGeneralAndAdministration | 33.30M | 27.75M | 28.95M | 27.14M |
| GeneralAndAdministrativeExpense | 33.30M | 27.75M | 28.95M | 27.14M |
| OtherGandA | 33.30M | 27.75M | 28.95M | 27.14M |
| TotalRevenue | 0.00 | 0.00 | 8.09M | 13.62M |
| OperatingRevenue | 0.00 | 0.00 | 8.09M | 13.62M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 40.47M | 20.39M | 19.56M | 7.36M |
| ShareIssued | 40.47M | 20.39M | 19.56M | 7.36M |
| TotalDebt | 24.18M | 26.27M | 28.55M | 2.06M |
| TangibleBookValue | 137.25M | 126.48M | 211.67M | 208.21M |
| InvestedCapital | 137.25M | 126.48M | 211.67M | 208.21M |
| WorkingCapital | 127.05M | 115.22M | 197.13M | 199.01M |
| NetTangibleAssets | 137.25M | 126.48M | 211.67M | 208.21M |
| CapitalLeaseObligations | 24.18M | 26.27M | 28.55M | 2.06M |
| CommonStockEquity | 137.25M | 126.48M | 211.67M | 208.21M |
| TotalCapitalization | 137.25M | 126.48M | 211.67M | 208.21M |
| TotalEquityGrossMinorityInterest | 137.25M | 126.48M | 211.67M | 208.21M |
| StockholdersEquity | 137.25M | 126.48M | 211.67M | 208.21M |
| GainsLossesNotAffectingRetainedEarnings | 47.00K | 15.00K | -68.00K | -45.00K |
| OtherEquityAdjustments | 47.00K | 15.00K | -68.00K | -45.00K |
| RetainedEarnings | -783.45M | -658.75M | -562.74M | -476.76M |
| AdditionalPaidInCapital | 920.61M | 785.20M | 774.45M | 685.01M |
| CapitalStock | 40.00K | 20.00K | 20.00K | 7.00K |
| CommonStock | 40.00K | 20.00K | 20.00K | 7.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 51.42M | 38.46M | 48.59M | 24.17M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 21.16M | 23.94M | 26.08M | 568.00K |
| OtherNonCurrentLiabilities | 96.00K | |||
| LongTermDebtAndCapitalLeaseObligation | 21.16M | 23.94M | 25.98M | 568.00K |
| LongTermCapitalLeaseObligation | 21.16M | 23.94M | 25.98M | 568.00K |
| CurrentLiabilities | 30.26M | 14.52M | 22.51M | 23.60M |
| OtherCurrentLiabilities | 3.15M | 24.00K | 14.00K | 35.00K |
| CurrentDeferredLiabilities | 0.00 | 8.08M | ||
| CurrentDeferredRevenue | 0.00 | 8.08M | ||
| CurrentDebtAndCapitalLeaseObligation | 3.02M | 2.32M | 2.56M | 1.50M |
| CurrentCapitalLeaseObligation | 3.02M | 2.32M | 2.56M | 1.50M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.22M | 5.95M | 8.37M | 3.08M |
| PayablesAndAccruedExpenses | 17.87M | 6.25M | 11.56M | 10.91M |
| CurrentAccruedExpenses | 13.63M | 4.21M | 8.32M | 6.44M |
| Payables | 4.24M | 2.03M | 3.24M | 4.46M |
| AccountsPayable | 4.24M | 2.03M | 3.24M | 4.46M |
| TotalAssets | 188.66M | 164.94M | 260.25M | 232.38M |
| TotalNonCurrentAssets | 31.36M | 35.20M | 40.61M | 9.77M |
| OtherNonCurrentAssets | 2.32M | 2.04M | 2.01M | 2.16M |
| NetPPE | 29.04M | 33.16M | 38.61M | 7.60M |
| AccumulatedDepreciation | -13.03M | -12.73M | -10.96M | -11.66M |
| GrossPPE | 42.07M | 45.90M | 49.56M | 19.27M |
| Leases | 470.00K | 481.00K | 384.00K | 4.71M |
| ConstructionInProgress | 879.00K | 410.00K | 1.72M | 1.49M |
| OtherProperties | 38.70M | 42.68M | 45.37M | 11.86M |
| MachineryFurnitureEquipment | 2.02M | 2.33M | 2.10M | 1.20M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 157.30M | 129.73M | 219.64M | 222.61M |
| OtherCurrentAssets | 1.65M | 2.11M | 3.00M | 8.71M |
| PrepaidAssets | 6.73M | 3.98M | 2.91M | 6.01M |
| Receivables | 0.00 | 110.00K | ||
| AccountsReceivable | 0.00 | 110.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 148.92M | 123.64M | 213.72M | 207.78M |
| OtherShortTermInvestments | 68.69M | 49.62M | 58.34M | 88.64M |
| CashAndCashEquivalents | 80.23M | 74.02M | 155.38M | 119.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -100.67M | -95.69M | -100.99M | -79.05M |
| RepurchaseOfCapitalStock | -5.11M | 0.00 | ||
| RepaymentOfDebt | -473.00K | 0.00 | -66.00K | 0.00 |
| IssuanceOfDebt | 0.00 | 2.14M | 0.00 | |
| IssuanceOfCapitalStock | 127.23M | 2.97M | 72.55M | 134.88M |
| CapitalExpenditure | -654.00K | -1.51M | -3.02M | -1.28M |
| EndCashPosition | 82.19M | 75.85M | 157.22M | 121.21M |
| BeginningCashPosition | 75.85M | 157.22M | 121.21M | 155.07M |
| ChangesInCash | 6.34M | -81.37M | 36.01M | -33.87M |
| FinancingCashFlow | 122.44M | 3.12M | 74.83M | 134.99M |
| CashFlowFromContinuingFinancingActivities | 122.44M | 3.12M | 74.83M | 134.99M |
| ProceedsFromStockOptionExercised | 794.00K | 148.00K | 203.00K | 107.00K |
| NetCommonStockIssuance | 122.12M | 2.97M | 72.55M | 134.88M |
| CommonStockPayments | -5.11M | 0.00 | ||
| CommonStockIssuance | 127.23M | 2.97M | 72.55M | 134.88M |
| NetIssuancePaymentsOfDebt | -473.00K | 0.00 | 2.08M | 0.00 |
| NetLongTermDebtIssuance | -473.00K | 0.00 | 2.08M | 0.00 |
| LongTermDebtPayments | -473.00K | 0.00 | -66.00K | 0.00 |
| LongTermDebtIssuance | 0.00 | 2.14M | 0.00 | |
| InvestingCashFlow | -16.09M | 9.69M | 59.16M | -91.09M |
| CashFlowFromContinuingInvestingActivities | -16.09M | 9.69M | 59.16M | -91.09M |
| NetInvestmentPurchaseAndSale | -15.44M | 11.20M | 30.05M | -89.81M |
| SaleOfInvestment | 188.90M | 128.63M | 212.81M | 51.44M |
| PurchaseOfInvestment | -204.34M | -117.43M | -182.76M | -141.25M |
| NetBusinessPurchaseAndSale | 0.00 | 31.52M | 0.00 | |
| SaleOfBusiness | 0.00 | 31.52M | 0.00 | |
| NetPPEPurchaseAndSale | -649.00K | -1.51M | -2.42M | -1.28M |
| SaleOfPPE | 5.00K | 0.00 | 600.00K | 0.00 |
| PurchaseOfPPE | -654.00K | -1.51M | -3.02M | -1.28M |
| OperatingCashFlow | -100.01M | -94.18M | -97.98M | -77.76M |
| CashFlowFromContinuingOperatingActivities | -100.01M | -94.18M | -97.98M | -77.76M |
| ChangeInWorkingCapital | 2.85M | -8.87M | -3.69M | -23.04M |
| ChangeInOtherWorkingCapital | -8.08M | -12.64M | ||
| ChangeInOtherCurrentLiabilities | -1.68M | -1.74M | ||
| ChangeInPayablesAndAccruedExpense | 6.97M | -7.73M | 586.00K | -1.05M |
| ChangeInAccruedExpense | 4.77M | -6.97M | 5.83M | -2.25M |
| ChangeInPayable | 2.21M | -764.00K | -5.25M | 1.21M |
| ChangeInAccountPayable | 2.21M | -764.00K | -5.25M | 1.21M |
| ChangeInPrepaidAssets | -2.44M | 598.00K | 3.69M | -9.25M |
| ChangeInReceivables | 0.00 | 110.00K | -110.00K | |
| ChangesInAccountReceivables | 0.00 | 110.00K | -110.00K | |
| OtherNonCashItems | 7.70M | 2.90M | -18.48M | -81.00K |
| StockBasedCompensation | 10.52M | 7.62M | 7.54M | 13.37M |
| AmortizationOfSecurities | -3.59M | -2.41M | 233.00K | 1.12M |
| DepreciationAmortizationDepletion | 2.46M | 2.58M | 2.41M | 2.96M |
| DepreciationAndAmortization | 2.46M | 2.58M | 2.41M | 2.96M |
| Depreciation | 2.46M | 2.58M | 2.41M | 2.96M |
| OperatingGainsLosses | 4.75M | 374.00K | 92.00K | |
| GainLossOnInvestmentSecurities | 4.75M | |||
| GainLossOnSaleOfPPE | 374.00K | 0.00 | 92.00K | |
| NetIncomeFromContinuingOperations | -124.70M | -96.02M | -85.98M | -72.19M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SLDB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|